Taysha Gene Therapies (NASDAQ:TSHA) Price Target Cut to $7.00

Taysha Gene Therapies (NASDAQ:TSHA) had its target price cut by investment analysts at Piper Sandler from $9.00 to $7.00 in a research report issued on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target points to a potential upside of 224.07% from the company’s current price.

Several other analysts also recently issued reports on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, June 18th. BMO Capital Markets initiated coverage on Taysha Gene Therapies in a research note on Thursday, June 27th. They set an “outperform” rating and a $5.00 target price for the company. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Jefferies Financial Group reiterated a “buy” rating and set a $8.00 target price (up from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $6.60.

Taysha Gene Therapies Stock Down 4.4 %

TSHA opened at $2.16 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.38 and a current ratio of 3.38. Taysha Gene Therapies has a 1 year low of $0.61 and a 1 year high of $4.32. The firm has a 50 day moving average price of $2.96 and a 200 day moving average price of $2.43. The company has a market cap of $403.96 million, a PE ratio of -4.41 and a beta of 0.42.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The company had revenue of $3.41 million during the quarter, compared to the consensus estimate of $3.70 million. During the same quarter last year, the company earned ($0.28) earnings per share. Sell-side analysts expect that Taysha Gene Therapies will post -0.43 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Paul B. Manning acquired 1,333,333 shares of Taysha Gene Therapies stock in a transaction that occurred on Thursday, June 27th. The shares were purchased at an average cost of $2.25 per share, for a total transaction of $2,999,999.25. Following the completion of the purchase, the insider now directly owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds have recently added to or reduced their stakes in TSHA. Howard Capital Management Inc. bought a new stake in Taysha Gene Therapies in the fourth quarter valued at $25,000. Victory Capital Management Inc. acquired a new position in shares of Taysha Gene Therapies during the fourth quarter valued at $28,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Taysha Gene Therapies during the fourth quarter valued at $31,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Taysha Gene Therapies during the fourth quarter valued at $38,000. Finally, Cannon Global Investment Management LLC acquired a new position in shares of Taysha Gene Therapies during the first quarter valued at $69,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.